Mike Rothe ist the CEO of IBA Lifesciences in Göttingen, Germany. He has extensive biotech industry experience and expertise in building successful life science companies. His involvement in biotechnology started as a visiting scientist at Genentech, Inc. (South San Francisco, USA) in 1992. From 1994 to early 1999, he was a Staff Scientist and Team Leader at Tularik, Inc. (South San Francisco, USA). In 1999, Dr. Rothe joined DeveloGen AG (Göttingen, Germany) as Vice President, Research and Development and later served as its Chief Scientific Officer. In July 2001, he co-founded U3 Pharma AG (Munich, Germany) and assumed the roles of Managing Director and CSO. He was instrumental in the acquisition of U3 Pharma by Daiichi Sankyo in 2008. From 2009 to 2012 he served as CEO and Member of the Board of Directors of Igenica, Inc. (Burlingame, USA). Prior to joining IBA GmbH, he was CEO of ImmunoQure AG (Munich, Germany) and CEO and Delegate of the Board of Directors of ImmunoQure Research AG (Zurich, Switzerland). Dr. Rothe studied biochemistry at the University of Tübingen before receiving his Ph.D. from the University of Munich and being awarded the Otto-Hahn Medal of the Max-Planck-Society. He is the author of numerous scientific articles and international patents.